1 
2 
O 
O 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
47 
pies which should underlie the conduct, applications, and 
use of recombinant DXA activities; 
(3) conduct a comprehensive review and critique of 
. the regulations promulgated under part I of title IV of 
the Public Ilealth Service Act; and 
(4) on the basis of the activities conducted under 
paragraphs (1), (2), and (3) make recommendations 
to the Congress and Secretary of Health, Education, and 
"Welfare (A) regarding the best approaches for assuring 
the safest and most appropriate applications and uses of 
recombinant DXA, if any ; and (B) for any modifica- 
tion or expansion of such part I which tne Commission 
determines is necessary. 
(b) In carrying out subsection (a), die Commission 
shall consider at least the following: 
(1) The protection of personnel engaged in recom- 
binant DXA activities and die general public from the 
dangers of recombinant DXA activities. 
(2) The role of assessment of risk-benefit criteria 
in the determination of the appropriateness of activities 
involving recombinant DXA. 
(3) Appropriate guidelines for the conduct of re- 
combinant DXA activities. 
(4) Mechanisms for evaluating and monitoring 
[ 665 ] 
